Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134980 | 1.00 | ADRB3 (0.53) | ADRB3ADRB1GHSRNPC1POLB | |
| SCHEMBL6134084 | 0.93 | ADRB3 (0.62) | ADRB3ADRB1 | |
| SCHEMBL6134081 | 0.93 | ADRB3 (0.62) | ADRB3ADRB1 | |
| SCHEMBL6133712 | 0.92 | ADRB3 (0.43) | ADRB3ADRB1 | |
| SCHEMBL6133709 | 0.92 | ADRB3 (0.43) | ADRB3ADRB1 | |
| SCHEMBL6590397 | 0.89 | ADRB3 (0.63) | ADRB3ADRB1 | |
| SCHEMBL6590393 | 0.89 | ADRB3 (0.63) | ADRB3ADRB1 | |
| SCHEMBL6134354 | 0.88 | ADRB3 (0.65) | ADRB3ADRB1 | |
| SCHEMBL6134358 | 0.88 | ADRB3 (0.65) | ADRB3ADRB1 | |
| SCHEMBL6133670 | 0.88 | ADRB3 (0.64) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ASTELLAS PHARMA INC. (JP) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885GHSR 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.